Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
75 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Show Display Options
RSS Create an RSS feed from your search for:
"Multiple Sclerosis, Chronic Progressive"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Cyclophosphamide (drug);   Drug: Methylprednisolone (drug)
2 Completed Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
3 Completed China Betaferon Adherence, Coping and Nurse Support Study
Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
4 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
5 Recruiting Intrathecal Rituximab in Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Nervous System Diseases
Interventions: Drug: Rituximab IT;   Drug: methylprednisolone IV;   Drug: Rituximab IV
6 Not yet recruiting Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);   Drug: Interferon-beta
7 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
8 Recruiting Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Intervention: Other: Brain MRI
9 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
10 Completed Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
11 Recruiting Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: Dimethyl Fumarate;   Drug: Placebo Oral Capsule
12 Not yet recruiting Hydroxychloroquine in Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Intervention: Drug: Hydroxychloroquine
13 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
14 Active, not recruiting Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Condition: Multiple Sclerosis
Intervention: Drug: BG00012 (DMF) (Tecfidera®.)
15 Active, not recruiting A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: Laquinimod;   Drug: Placebo
16 Recruiting Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
Conditions: Primary Progressive Multiple Sclerosis;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: Andrographolides;   Drug: placebo
17 Recruiting A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Rituximab
18 Active, not recruiting A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Interventions: Drug: Fampridine;   Drug: Placebo
19 Recruiting Measuring Active Microglia in Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Intervention: Radiation: [C11]PK-1195 PET scan
20 Completed Tear Analysis in the Diagnosis of Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Intervention: Procedure: tears sampling

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.